Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice

The aim of this study was to investigate FDG-PET (fluorodeoxyglucose positron emission tomography) imaging in the management of prostate cancer. Twenty-two patients were studied during different disease phases of prostate cancer, for staging or restaging to clarify specific clinical questions. FDG-PET was performed encompassing the thorax, abdomen and pelvis using the Penn PET 300H scanner. Scanning was begun 60 min after 18 F fluorodeoxyglucose marker. Patients were catheterized and administered diuretics to minimize urinary activity. Information obtained with FDG-PET was concordant with findings from other investigations in 7/22 (32%) patients, discordant in 15/22 (68%) patients and equivalent in one patient (4%). PET indicated progressive disease in five patients with prostate-specific antigen (PSA) <4 ng/L. The impact on management of the patients was high in 46% of cases, low in 41% and for 14% there was no impact on management. The accuracy of FDG-PET was 72% (95% CI 50-89) as confirmed by invasive diagnostics/follow-up. FDG-PET can provide useful information and improve the clinician's decision on further management procedures in selected patients with low PSA and bone or lymph node changes. A negative PET scan in prostate cancer should be interpreted with caution.

[1]  C Coley,et al.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. , 2001, Urology.

[2]  N. Lee,et al.  Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. , 2000, International journal of radiation oncology, biology, physics.

[3]  Sven N. Reske,et al.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma , 2000, European Journal of Nuclear Medicine.

[4]  M. van der Graaf,et al.  Prostate cancer staging using imaging , 2000, BJU international.

[5]  C. Kao,et al.  Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. , 2000, Anticancer research.

[6]  N. Sadato,et al.  The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. , 1999, Japanese journal of clinical oncology.

[7]  Sanz,et al.  Positron emission tomography with 18fluorine‐labelled deoxyglucose: utility in localized and advanced prostate cancer , 1999, BJU international.

[8]  J. Coebergh,et al.  Striking increase in incidence of prostate cancer in men aged < 60 years without improvement in prognosis , 1999, British Journal of Cancer.

[9]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  A. Belldegrun,et al.  Positron emission tomography in urological oncology. , 1998, The Journal of urology.

[11]  J. Ruhlmann,et al.  Possible role of FDG-PET in the evaluation of urologic malignancies. , 1997, Anticancer research.

[12]  S. Rosenthal,et al.  Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. , 1996, Clinical nuclear medicine.

[13]  G Jakse,et al.  Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. , 1996, The Journal of urology.

[14]  M. Rudoni,et al.  The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer , 1995, European Journal of Nuclear Medicine.

[15]  M. Terris,et al.  Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. , 2001, Urology.

[16]  W. Digby,et al.  The current status of positron emission tomography. , 2000, Radiology management.